The number that frames this story is not about a device. It is estimated that roughly half of people with cystic fibrosis worldwide have never been diagnosed.
That figure, cited by Susanna McColley of Lurie Children's Hospital of Chicago in the hospital's announcement of a new wearable sweat test, explains why hardware matters. Without treatment, she said, life expectancy is under five years, against a projected median survival of 66 years in the United States today. CFTR modulator drugs have changed the course of the disease, but only for people who have been identified.
Diagnosis depends on sweat chloride testing, a procedure that requires trained personnel, bulky instrumentation, and an accredited center, which in practice means a children's hospital. For a family in a rural county or a country with few specialized labs, that is a wall.
Two Stickers, a Phone, and a Dollar
The system, called CF SWIFT, was built by John Rogers's bioengineering team at Northwestern University's Querrey Simpson Institute for Bioelectronics with the Cystic Fibrosis Center at Lurie Children's. It appeared in npj Digital Medicine.
The workflow replaces a laboratory with two flexible patches applied in sequence to the same spot on the skin. The first stimulates sweat production using a chemical stimulant and a small button battery. The second collects the sweat. A smartphone app photographs the collection patch and calculates chloride concentration by measuring changes in color density.
The system needs only microliters of sweat, produces a visually interpretable result without external instrumentation, and brings the cost to around one dollar per test. The whole procedure takes under an hour.
The patches are small, flexible, and gentle enough for a newborn's skin, addressing a specific weakness of conventional testing. Standard pilocarpine iontophoresis often fails to collect an adequate sweat sample in babies, forcing repeat visits at exactly the moment a diagnosis is most time-sensitive. An earlier generation of this technology, reported in Science Translational Medicine, collected 33 percent more sweat than standard devices.
Clinical evaluation involved 55 participants at a single pediatric CF center: three healthy volunteers and 52 people with cystic fibrosis or related conditions, from infancy to age 21. Each underwent both conventional sweat testing and the sticker method, and the results showed strong agreement.
A Second Device Doing a Different Job
CF SWIFT is aimed at diagnosis. A separate wearable within the same broader research ecosystem focuses on what happens afterward.
Northwestern Medicine investigators, working with the university spinout Epicore Biosystems, developed a microfluidic sweat patch called the CF Patch and reported results in PNAS last year. Twenty adults with cystic fibrosis and seven healthy controls completed a clinic-based sweat chloride test and then five remote exercise sessions over 14 days while wearing the patch. In-clinic measurements correlated strongly with laboratory chloridometry, though the correlation between remote and laboratory results was weaker among patients than among healthy volunteers.
The more interesting result was incidental. Among patients taking CFTR modulators, sweat chloride varied considerably from day to day, more than in healthy volunteers. Senior author Manu Jain framed the question directly in a Northwestern summary: whether day-to-day swings might signal that the drugs are not working as well as they could. That variability undercuts the assumption that a single in-clinic measurement reliably captures modulator performance.
The two devices are not competitors. One tries to find people who have not been diagnosed. The other tries to manage people who have.
Neither One Is Available Yet
This is diagnostic technology under development, not a product a family can buy.
The CF SWIFT team plans multicenter validation before clinical rollout, focused specifically on younger infants, since most sweat tests in the United States are performed in the first weeks of life, and that is where conventional testing most often fails. McColley said FDA approval will be necessary for clinical use.
Both steps are substantial. A device validated in 55 patients aged infancy to 21 at one center is not a device validated for newborns across many centers, and regulatory review is not a formality for a diagnostic that would guide whether a child starts lifelong therapy. The researchers also emphasized that the CF Patch is not intended to replace traditional sweat chloride assessment.
Readers should know who stands where. Three authors on the CF SWIFT paper, including Rogers, are affiliated with Epicore Biosystems, which develops and commercializes microfluidic sweat devices. McColley is an unpaid clinical advisor to Epicore and a paid advisor to Vertex Pharmaceuticals, which makes CFTR modulator drugs. The paper states that CF SWIFT is not owned by Epicore. Rogers is an associate editor of npj Digital Medicine and was not involved in reviewing the manuscript.
What Families Should Do in the Meantime
More than 40,000 children and adults in the United States live with cystic fibrosis, according to the Cystic Fibrosis Foundation. In this country, newborn screening is the front door, and it works.
Families should follow their state newborn screening program and the guidance of their CF center. Concerns about a child's screening result belong with a pediatrician now, not on hold waiting for a technology that has not been cleared.
The access problem these devices target is real but geographically uneven. In the United States, it mostly looks like a travel burden and scheduling delay for families far from an accredited center. Globally, it looks like there is no testing infrastructure at all, which is where a one-dollar, equipment-free test would matter most, and where regulatory clearance in a wealthy country does not automatically translate into availability.
Key Questions Answered
What does the sweat test measure?
Chloride concentration in sweat. Mutations in the CFTR gene disrupt chloride transport across cell membranes, leading to abnormally salty sweat.
What is CF SWIFT?
A wearable system of two flexible stickers that stimulate and collect sweat, plus a smartphone app that reads chloride concentration from color density changes.
How many people were tested?
Fifty-five participants at one pediatric center, including 52 with cystic fibrosis or related conditions and three healthy volunteers, from infancy to age 21.
Is it available now?
No. Multicenter validation in younger infants is planned, and FDA approval is still required.
What is the CF Patch?
A separate wearable microfluidic patch for remote monitoring, rather than diagnosis, that detected substantial day-to-day sweat chloride variability in patients on CFTR modulators.
What should US families rely on today?
State newborn screening programs and guidance from an accredited CF center. Questions about a screening result should go to a pediatrician.
